Published on 17 April 2024

Researchers at University of Oxford are recruiting volunteers with type 1 diabetes for this groundbreaking study.


Researchers at the University of Oxford are recruiting for the second Vertex Clinical Trial of transplantation of stem cell-derived pancreatic islets – the VX264 Trial.


This latest trial is for people with type 1 diabetes over the age of 18 and with good awareness of hypoglycaemia (low blood glucose). It involves transplanting stem cell-derived islets in immune-protective capsules under the abdominal wall. People in this trial will not need to take immunosuppression (anti-rejection medication).


Professor Paul Johnson Director of the Oxford Islet Isolation and Islet Transplant Programmes and Professor of Paediatric Surgery at the University of Oxford said: “Islet transplantation has been increasingly successful over the last couple of decades in a selected group of patients. However, the requirement for life-long immunosuppression has limited its application to a wider group of people. If this immunosuppression-free trial is successful, it could be a game-changer for the management of type 1 diabetes, ultimately paving the way for our ultimate goal which is to be able to reverse type 1 diabetes in children soon after diagnosis.”


Oxford is one of only five centres in Europe to have been selected to be conducting this trial. 

I would like to make a regular donation of


I would like to make a single donation of

There are lots of ways to raise money to support
people living with all forms of diabetes.

Bake, Swim, Cycle, Fly ... Do It For DRWF!

Fundraise with us